Mr. Roy has extensive biotechnology commercialization and business development expertise, with over 13 years at Amgen Inc. He headed up Strategy, Planning and Operations for the launch of Aranesp®, a multi-billion dollar oncology drug. As Director of Amgen's Department of Alliance Management, he managed ~70 corporate partnerships, representing over $100 Million in annual R&D expenditure.

Dr. Donoghue has 20 years in the drug development field, at Hoechst-Roussel Agri-Vet Company, Heska Corporation and PR Pharmaceuticals, Inc. with 4 NADAs, 3 USDA licenses and 2 EPA registrations. She has extensive regulatory experience across both animal and human programs, from project initiation through scale up to commercial GMP manufacturing, and GLP/GCP clinical trials.

Dr. Johnson has 20 years of experience in the pharmaceutical industry covering all areas of CMC activities. Doug Johnson spent over 10 years as Vice President of Manufacturing and Pharmaceutical Sciences at Allos Therapeutics, managing and integrating outsourced chemistry and manufacturing activities for small molecule cancer drugs. He has been involved in the preparation of 4 NDAs and 10 INDs.

Dr. Thamm is an ACVIM Diplomat and Associate Professor of Oncology at Colorado State University. He has extensive oncology clinical experience, conducting over 24 animal cancer trials and was one of the lead veterinary investigators on VDC-1101. Dr. Thamm is an internationally recognized veterinary cancer opinion leader.

Dr. Opgenorth has over 20 years of biopharmaceutical R&D experience. As a former Divisional Vice President of Discovery Research at Abbott Laboratories, he led teams that brought 10 compounds from discovery research into human clinical trials. Dr. Opgenorth is a VetDC founder and is Vice President, CSU Ventures.